SCHEMBL969373

SCHEMBL969373

CSc1ccccc1-c1nnc(S)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.42
LMNA P02545 3/20 0.42
RXFP1 Q9HBX9 3/20 0.42
ALDH1A1 P00352 12/20 0.41
RAB9A P51151 6/20 0.41
HPGD P15428 6/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
IDO1 P14902 1/20 0.39
NPC1 O15118 5/20 0.39
NPSR1 Q6W5P4 3/20 0.39
NISCH Q9Y2I1 1/20 0.38
KMT2A Q03164 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11334511 0.79 ALDH1A1 (0.59) KDM4ELMNARXFP1ALDH1A1RAB9A
SCHEMBL11025136 0.77 ALDH1A1 (0.50) KDM4ERXFP1ALDH1A1RAB9AHPGD
SCHEMBL971700 0.77 ALDH1A1 (0.49) KDM4ELMNAALDH1A1RAB9AHPGD
SCHEMBL968101 0.74 KDM4E (0.61) KDM4ERXFP1ALDH1A1RAB9AHPGD
SCHEMBL970693 0.73 ALDH1A1 (0.62) KDM4ELMNARXFP1ALDH1A1RAB9A
SCHEMBL22469017 0.73 GUSB (0.46) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL8046899 0.73 HDAC1 (0.43) KDM4ELMNAALDH1A1RAB9AHPGD
SCHEMBL971940 0.72 KDM4E (0.66) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL968457 0.72 ACHE (0.44) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL1531740 0.70 PTPN11 (0.47) KDM4ELMNAALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 KDM4E 3077/4885LMNA 48/4885RXFP1 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.